Trials / Recruiting
RecruitingNCT06855498
Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib
A Phase 3b, Multicenter, Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib
- Status
- Recruiting
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 600 (estimated)
- Sponsor
- Incyte Corporation · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Rollover study for participants from predetermined, Incyte-sponsored parent clinical trials of povorcitinib.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | povorcitinib | Study drug will be taken orally as defined by the protocol. |
Timeline
- Start date
- 2025-02-28
- Primary completion
- 2028-02-28
- Completion
- 2028-02-28
- First posted
- 2025-03-03
- Last updated
- 2026-04-08
Locations
316 sites across 21 countries: United States, Argentina, Australia, Austria, Belgium, Bulgaria, Canada, Chile, Czechia, Denmark, France, Germany, Greece, Hungary, Italy, Netherlands, Poland, South Korea, Spain, Switzerland, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06855498. Inclusion in this directory is not an endorsement.